After a few years in biotech, Mike Quigley, Ph.D., is returning to the pharma fold, taking up the top science spot at Sanofi.

Sanofi named a new chief scientific officer this week, part of a series of moves aimed at redefining the company.

Sanofi has appointed Mike Quigley, a former executive at Gilead and Bristol Myers Squibb, as the French pharma's next chief ...

Banks and other lenders are readying over €10B ($11.1B) in funding as New York-based buyout firm Clayton Dubilier & Rice and its French rival PAI Partners compete for Sanofi’s (NASDAQ ...

NEW YORK (Reuters) -Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a variety of new drugs and is not facing imminent ...

Sanofi will gain exclusivity rights to Ventyx Biosciences’ CNS-penetrant candidate VTX3232 as part of a $27m deal. Under the terms of the agreement, Sanofi will buy 70,601 shares of Ventyx’s ...

Private equity firms Clayton Dubilier & Rice and PAI Partners have forwarded binding bids for Sanofi’s (NASDAQ:SNY) consumer health division as the French pharma giant looks to sell the unit in ...

Analyst Eric Le Berrigaud from Stifel Nicolaus maintained a Buy rating on Sanofi (SNYNF – Research Report) and increased the price target to €123.00 from €111.00. Eric Le Berrigaud’s ...